Lung Cancer, Non-small Cell

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
TagrissoPhase 21 trial
Active Trials
NCT02824952Unknown40Est. Dec 2022
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Genomic profiles detectionN/A1 trial
Active Trials
NCT05598528RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaTagrisso
City TherapeuticsGenomic profiles detection

Clinical Trials (2)

Total enrollment: 40 patients across 2 trials

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Start: Nov 2018Est. completion: Dec 202240 patients
Phase 2Unknown
NCT05598528City TherapeuticsGenomic profiles detection

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Start: Sep 2021Est. completion: Dec 2026
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 40 patients
2 companies competing in this space